Fulcrum Therapeutics Inc’s recently made public that its Principal Accounting Officer Tourangeau Greg unloaded Company’s shares for reported $1831.0 on May 07 ’24. In the deal valued at $7.76 per share,236 shares were sold. As a result of this transaction, Tourangeau Greg now holds 11,571 shares worth roughly $40382.79.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Tourangeau Greg sold 4,884 shares, generating $57,219 in total proceeds. Upon selling the shares at $11.72, the Vice President, Finance now owns 11,807 shares.
Before that, Sapir Alex bought 43,360 shares. Fulcrum Therapeutics Inc shares valued at $492,028 were divested by the insider at a price of $11.35 per share. As a result of the transaction, Sapir Alex now holds 43,360 shares, worth roughly $0.15 million.
H.C. Wainwright downgraded its Fulcrum Therapeutics Inc [FULC] rating to a Neutral from a a Buy in a research note published on September 13, 2024; the price target was decreased to $4 from $17. A number of analysts have revised their coverage, including Stifel’s analysts, who decreased its forecast for the stock in mid September from “a Buy” to “a Hold”. RBC Capital Mkts also remained covering FULC and has decreased its forecast on September 12, 2024 with a “Sector perform” recommendation from previously “an Outperform” rating. Leerink Partners revised its rating on September 12, 2024. It rated FULC as “a Market perform” which previously was an “an Outperform”.
Price Performance Review of FULC
On Tuesday, Fulcrum Therapeutics Inc [NASDAQ:FULC] saw its stock jump 9.75% to $3.49. Over the last five days, the stock has lost -58.60%. Fulcrum Therapeutics Inc shares have fallen nearly -48.30% since the year began. Nevertheless, the stocks have fallen -22.27% over the past one year. While a 52-week high of $13.70 was reached on 03/06/24, a 52-week low of $2.87 was recorded on 09/12/24. SMA at 50 days reached $8.25, while 200 days put it at $7.90.
Levels Of Support And Resistance For FULC Stock
The 24-hour chart illustrates a support level at 3.18, which if violated will result in even more drops to 2.86. On the upside, there is a resistance level at 3.81. A further resistance level may holdings at 4.12. The Relative Strength Index (RSI) on the 14-day chart is 24.41, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.78, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 90.29%. Stochastics %K at 6.24% indicates the stock is a buying.
How much short interest is there in Fulcrum Therapeutics Inc?
A steep rise in short interest was recorded in Fulcrum Therapeutics Inc stocks on 2024-08-30, growing by 0.37 million shares to a total of 8.06 million shares. Yahoo Finance data shows the prior-month short interest on 2024-07-31 was 7.68 million shares. There was a rise of 4.63%, which implies that there is a positive sentiment for the stock.
